Minireviews
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 163-180
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.163
Table 1 Characteristics of hepatocellular carcinoma patients receiving immunotherapy as a downstaging or bridging approach to liver transplantation
No.
Ref.
Age
Sex
Underlying liver disease
MTD (cm)
Pathology milan in/out
Cycles/duration
Immunotherapy
Days before LT
Post-LT follow-up (mo)
Initial immunosuppression
Rejection
1Tabrizian et al[6]69MNone10Milan out within UCSF21 cyclesNivolumab1823Tapering steroids + tacrolimus + MMFNo
2Tabrizian et al[6]56FHCV5.4Milan out within UCSF8 cyclesNivolumab2222Tapering steroids + tacrolimus + MMFNo
3Tabrizian et al[6]58MHBV21Milan in32 cyclesNivolumab122Tapering steroids + tacrolimus + MMFNo
4Tabrizian et al[6]63MHCV, HIV4.4Milan in4 cyclesNivolumab221Tapering steroids + tacrolimus + MMFNo
5Tabrizian et al[6]30MHBV3.2Milan in25 cyclesNivolumab2216Tapering steroids + tacrolimus + MMFMild
6Tabrizian et al[6]63MHBV2Milan in4 cyclesNivolumab1314Tapering steroids + tacrolimus + MMFNo
7Tabrizian et al[6]66MHBV2.5Milan in9 cyclesNivolumab25314Tapering steroids + tacrolimus + MMFNo
8Tabrizian et al[6]55FHBV2.8Milan in12 cyclesNivolumab78Tapering steroids + tacrolimus + MMFNo
9Tabrizian et al[6]53FNASH8.7Milan out within UCSF2 cyclesNivolumab308Tapering steroids + tacrolimus + MMFNo
10Schwacha-Eipper et al[7]66MAlcohol-associated liver cirrhosis6.4Milan out34 cyclesNivolumab10512NANo
11Nordness et al[8]65MHCV5.5Milan in2 yrNivolumab8Death at day 10Tacrolimus + MMF + steroidsYes